The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
The study evaluated patients with stage III/IV melanoma after complete tumor resection
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
Subscribe To Our Newsletter & Stay Updated
